PET scan tracer to image a brain enzyme linked to Alzheimer's

Development of class-IIa HDAC targeting PET probes for molecular imaging of disorders of the CNS

NIH-funded research State University New York Stony Brook · NIH-11197615

This project will use a new PET tracer to show levels of a brain enzyme called class‑IIa HDAC in people with Alzheimer's disease and in healthy volunteers.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionState University New York Stony Brook NIH-funded
Lab location1 site (Stony Brook, United States)
Project IDNIH-11197615 on NIH RePORTER

What this research studies

From my perspective as a patient, the team is developing a new radioactive tracer ([18F]NT311D) that can be seen on PET scans to map a brain enzyme thought to be involved in Alzheimer's. They will refine how the tracer is made, test it in animals, obtain IRB approval and an exploratory IND, and then offer PET scans to human volunteers. The scans aim to measure enzyme levels noninvasively and track changes over time. If everything goes well, this could be used in future studies to detect early disease or to see whether new drugs hit this target.

Who could benefit from this research

Good fit: Ideal candidates would be people with Alzheimer's disease or mild cognitive impairment, and older healthy volunteers who are willing and eligible to undergo PET imaging with an injected radiotracer.

Not a fit: People who cannot have PET scans (for example, pregnant individuals, those with medical conditions that preclude participation, or those unwilling to receive a radiotracer) or those without Alzheimer's-related brain changes are unlikely to benefit from this early imaging study.

Why it matters

Potential benefit: If successful, the tracer could allow earlier, noninvasive detection and monitoring of Alzheimer's-related biology and help guide development of new treatments.

How similar studies have performed: Brain PET tracers for amyloid and tau are well established, but imaging class‑IIa HDAC is novel with encouraging preclinical results and only limited human data so far.

Where this research is happening

Stony Brook, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer disease detectionAlzheimer syndromeAlzheimer's Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.